Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release May 24 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

The trial will evaluate the safety and efficacy of Usnoflast in ALS patients, with primary and secondary endpoints focused on functional and biological measures. This press release aims to inform investors and the exchange about the progress of Zydus Lifesciences' clinical research efforts.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 24, 2024, titled "Zydus Lifesciences announces completion of Enrolment for Phase II clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)."

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases